|Bid||6.16 x 800|
|Ask||6.21 x 900|
|Day's Range||5.60 - 5.92|
|52 Week Range||1.82 - 10.40|
|Beta (3Y Monthly)||-4.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 14, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
Davis-based crop technology company Arcadia Biosciences Inc. said it raised $9.2 million from a direct offering of its stock to institutional and accredited investors.
DAVIS, Calif., Sept. 10, 2019 /PRNewswire/ -- Arcadia Biosciences, Inc. (RKDA), a food ingredient company and proven leader in agricultural innovation, improving the quality and nutritional content of crops, today announced the closing of its previously announced registered direct offering of 1,318,828 shares of its common stock. The offering was priced at-the-market at a purchase price per share of $7.52, for gross proceeds of approximately $9.92 million. Additionally, in a concurrent private placement, Arcadia issued unregistered warrants to purchase up to 659,414 shares of common stock, representing 50 percent of the shares of common stock purchased in the registered direct offering.
On Thursday, the New York State Department of Health came out with a theory around vitamin E acetate being the culprit. Meanwhile, Washington, D.C. enacted a law that provides protections to government employees who consume medical marijuana. While many were investing in the cannabis space, Aurora Cannabis Inc. (NYSE: ACB) has started cashing out on some of its investments.
Arcadia Specialty Genomics, a hemp-focused operating unit of crop innovation company Arcadia Biosciences Inc (NASDAQ: RKDA ), announced this week plans for a new sun-grown hemp cultivation and agronomic ...
DAVIS, Calif., Sept. 6, 2019 /PRNewswire/ -- Arcadia Biosciences, Inc. (RKDA), a food ingredient company and proven leader in agricultural innovation, improving the quality and nutritional content of crops, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 1,318,828 shares of its common stock, at a purchase price per share of $7.5825, in a registered direct offering priced at-the-market. Additionally, Arcadia has agreed to issue to the investors unregistered warrants to purchase up to 659,414 shares of common stock. The warrants to purchase up to 659,414 shares of common stock have an exercise price of $7.52 per share, will be immediately exercisable, and will expire five and one-half years from the issue date.
DAVIS, Calif. , Sept. 4, 2019 /PRNewswire/ -- Arcadia Biosciences, Inc. (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, ...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
CFO of Arcadia Biosciences Inc (30-Year Financial, Insider Trades) Matthew T Plavan (insider trades) bought 8,000 shares of RKDA on 08/28/2019 at an average price of $8.73 a share. Continue reading...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Taronis Technologies (NASDAQ: TRNX ) shares ...
Shares of Davis-based Arcadia Biosciences Inc. rose more than 52% on Monday on a large revenue increase forecast by newly named CEO Matthew Plavan.
Shares of agricultural biotech company Arcadia Biosciences Inc. shot up 35% on Monday after the company said it expects total revenues in 2020 and 2021 to exceed $10 million and $30 million, respectively. The company said it expects to begin generating net cash from operations in 2021. Arcadia also announced that Chief Executive Raj Ketkar would retire in September and that the company's board had elected Chief Financial Officer Matthew Plavan as the company's new CEO. Shares of Arcadia have rocketed 174% in the year to date, while the S&P 500 has gained 14.7%.
Agricultural biotechnology company Arcadia Biosciences, Inc. (NASDAQ: RKDA) announced Monday that it has signed a binding term sheet agreement with Arista Cereal Technologies and Bay State Milling Company for the commercialization of its high-fiber wheat. Bay State Milling will become the exclusive commercial partner for the company’s high-fiber wheat in North America under Bay State Milling’s HealthSense brand portfolio. Arista, on the other hand, will obtain exclusive rights under Arcadia’s intellectual property in Australia, New Zealand, Japan, South Korea and Europe.
DAVIS, Calif., Aug. 26, 2019 /PRNewswire/ -- Arcadia Biosciences, Inc. (RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, announced today that Raj Ketkar, president and CEO, will retire effective September 1, 2019. In line with its succession plan, the board has appointed Matthew Plavan to chief executive officer and member of the board of directors. Plavan is succeeded by Pam Haley as Arcadia's new chief financial officer.
DAVIS, Calif., Aug. 26, 2019 /PRNewswire/ -- Arcadia Biosciences, Inc. (RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, today announced a binding term sheet agreement with Arista Cereal Technologies and Bay State Milling Company for commercialization of its high fiber resistant starch wheat in key wheat markets, including North America, Europe and parts of Asia.
A few notable names include former Heisman winner Ricky Williams, pro golfer Bubba Watson and NBA great Gary Payton. Former two-time World Series champion Shane Victorino is one of the latest to get involved. Victorino's Hawaii-based venture, Legacy Ventures Hawaii, recently partnered with Arcadia Biosciences (NASDAQ: RKDA) to launch a joint cultivation and extraction venture, Archipelago Ventures.
Warrior Trading is a content partner of Benzinga. This post did not go through the Benzinga Newsdesk. Well, it took a half a month of struggles, but this Thursday marks the first time in August that I’ve ...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Pivotal Software (NYSE: PVTL ) shares were ...
Company launches Archipelago™ Ventures, a strategic joint venture for superior hemp production and extraction in Hawaii DAVIS, Calif. , Aug. 14, 2019 /PRNewswire/ -- Arcadia Biosciences, Inc. (Nasdaq: ...
Shares of Arcadia Biosciences Inc. rose in active trading again on Tuesday, but pulled back sharply from an earlier peak, as the rocket ride of the past two sessions appears ready for a pause. The stock's gains have come after the food ingredients and nutritional oils company's joint venture with Biocerese Crop Solutions Corp. , Verdeca, said last week that its HB4 drought-tolerant soybeans received approval from the U.S. Department of Agriculture. The stock was up 2.2% on volume of of 1.2 million shares ahead of Tuesday's open, but had been up as much as 25.5% earlier in the premarket. The stock had run up 244% over the past two sessions, including a 124.4% rally on volume of 56.7 million shares on Friday and a 53.7% surge on volume of 38.8 million shares on Monday. The stock has now more than doubled year to date through Monday (up 119%), while the S&P 500 has gained 15.0%.
Shares of Arcadia Biosciences Inc. rocketed higher again Monday, running up 53% on heavy volume after jetting 124% higher the previous session, to pace the Nasdaq exchanges gainers. Trading volume was 25.4 million shares, compared with the full-day average of about 2 million shares, and after turning over 56.7 million shares on Friday. The stock more than doubled on Friday after Verdeca, a joint venture between Arcadia and Bioceres Crop Solutions Corp. said its HB4 drought-tolerant soybeans received approval from the U.S. Department of Agriculture. Arcadia's stock has now gained 15.6% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has lost 10.2% and the S&P 500 has edged up 2.2%. Arcadia's stock was back up toward levels last seen during the February-March rally, which was on the back of the company's announcement of a cannabis-focused business unit.
Shares in Davis-based Arcadia Biosciences Inc. shot up 124% Friday on news of a USDA approval for drought-tolerant soybeans the company has developed in a joint partnership with Bioceres Crop Solutions Corp.
Shares of Arcadia Biosciences Inc. rocketed 97.5% on very heavy volume Friday, after Verdeca, a joint venture between Arcadia and Bioceres Crop Solutions Corp. , said it received approval from the U.S. Department of Agriculture to commercialize its HB4 drought-tolerant soybeans. Trading volume in Arcadia's stock was 28.5 million shares, compared with the full-day average of about 127,000 shares. The rally comes after the stock closed at a record low of $1.92 on Monday Aug. 5. Bioceres's stock rose 6% in morning trading. "HB4 is a novel soybean trait that enhances the traditional herbicide tolerance package to provide yield stability across diverse environments," said Verdeca General Manager Martin Mariani Ventura. "Approval of this technology in the United States is a significant step for the successful commercialization of HB4 technology in the global soybean market." Arcadia's stock has still lost 22.7% over the past three months, while Bioceres shares have run 54.5% and the S&P 500 has gained 1.3%.
-- Novel trait stack expected to help growers facing climate and production challenges -- -- HB4 trait now has regulatory approval in more than 80 percent of the global soybean market -- DAVIS, Calif. ...